Messages from Orbit

August 2, 2019

Tracking to the Nth degree – aRMM Distribution Metrics

Over the years, a common question heard in consultations: “How do we track our distribution metrics for our aRMM’s?“ Many organizations continue to rely on metric […]
June 27, 2019

From Michelle’s Desk: DIA Global 2019

Reflecting back on the busy week with the Feith Team reaffirmed how valuable Orbit software is in solving the ongoing challenges in tracking Pharma’s complex procedural […]
June 21, 2019
Pharmacovigilance technology

From Michelle’s Desk: Improving Patient Safety

Our software may not be improving the lives of patients. But the people who use it are. Making medicines, therapies, & treatments to save or improve […]
June 18, 2019

From Michelle’s Desk: Intake, Filling Outlook’s Very Big Shoes

Email intake software for Adverse Events has big shoes to fill. It’s replacing Outlook, one of the most mature products of all time. Those big shoes […]
April 30, 2019

Orbit announces new Senior Director of Strategy and Business Development

The Feith Executive Team is pleased to announce Michelle Peralta as the new Senior Director of Strategy and Business Development for the Life Sciences Group. She […]
March 1, 2019
mountains

Build-vs-Buy: How implementing a pre-configured PV Tracking solution will get you there faster

Most Pharma companies rely on passive tools—such as spreadsheets and email—for tracking and managing their Risk Management Plans (RMPs) and Additional Risk Minimization Measures (ARMMs). However, […]
February 14, 2019

RMPs: Plan locally, track globally

Pharmaceutical companies encounter challenges with tracking and sharing CORE, EU, and Local implementation of their Risk Management Plans (RMPs). Orbit makes tracking RMPs easy, while improving […]
February 13, 2019

Lots of learning @ DIA

Over the past few weeks, at DIA PVRMS in Washington DC and DIA Europe in Vienna, we had a lot of exciting and interesting conversations, and […]
December 3, 2018

A New Years Resolution we can achieve in 2019

It’s not how much you CAN track, it’s how little you NEED to track At the beginning of each new project we work with our clients […]
September 17, 2018

Why is everyone so worried about their Additional RMMs?

Additional Risk Minimization Measures are invaluable for mitigating drug-related risks that are both severe and preventable. Having aRMMs in place often improves patient outcomes, yet aRMMs […]
April 11, 2018

Q&A: Introducing Orbit Compliance Center

Feith introduces Orbit, a new platform that’s flexible, validated and intuitive. Perfect for Tracking: ·         Risk Management Plans, Commitments and Additional Risk Minimization Measures ·         Aggregate Report […]
December 21, 2017

Happy New Year from Orbit

Happy New Year to Patient Safety and Regulatory Professionals. You are responsible for massive amounts of data, and the stakes are high—yet every day you work […]
July 25, 2017

Patient Support Programs: Eating the Elephant

Across the board, Pharmaceutical companies are looking to reduce the amount of effort they put into case processing. Case processing comprises a huge amount of manual […]
July 7, 2017

Risk Minimization in Modules V & XVI – Show, Don’t Tell

Modules V and XVI are closely related regulations providing requirements for Risk Minimization Measures (RMMs) that you’ll need to account for in your RMPs.  Where Module […]
March 13, 2017

Tracking your Signals in EVDAS

So you found a potential safety signal in Eudravigilance EVDAS… now what? The EMA introduced and made available (to MAH’s and national competent authorities) the Eudravigilance […]
February 27, 2017

Case Processing Evolution – Where do you fit?

In a webinar I gave last week, “Over Outlook? Simplify your PV mailbox with NLP technology,” I introduced a scale that I call “Case Processing Evolution.” These […]
February 13, 2017

Validated computer systems – a must for life sciences

For leaders in Pharma looking to implement a technology solution, one of the first considerations is validation—Can the system be validated, should it be validated, and […]